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Summary 
Tumors escape immunological rejection by a diversity of mechanisms. In this report, we dem- 
onstrate that the colon cancer cell SW620 expresses functional Fas ligand (FasL), the triggering 
agent of Fas receptor (FasR)-mediated apoptosis within the immune system. FasL mRNA and 
cell surface FasL were detected in SW620 cells using reverse transcription polymerase chain re- 
action (RT-PCR) and immunohistochemical staining, respectively. We show that SW620 kills 
Jurkat  T  cells  in  a  Fas-mediated  manner.  FasR-specific  antisense  oligonucleotide  treatment, 
which transiently inhibited FasR expression, completely protected Jurkat cells from killing by 
SW620.  FasL-specific antisense oligonucleotide treatment of SW620 inhibited its Jurkat-killing 
activity. FasL has recently been established as a mediator of immune privilege in mouse retina 
and testis.  Our finding that colon cancer cells express functional FasL suggests it may play an 
analogous role in bestowing immune privilege on human  tumors.  HT29  and  SW620  colon 
cancer cells were found to express FasR mRNA and cell surface FasR using RT-PCR and im- 
munofluorescence  flow cytometry,  respectively.  However,  neither  of these  cells  underwent 
apoptosis after treatment by the anti-FasR agonistic monoclonal antibody CH11.  Our results 
therefore suggest a Fas counterattack model for immune escape in colon cancer, whereby the 
cancer cells  resist  Fas-mediated T  cell cytotoxicity but  express functional  FasL,  an apoptotic 
death signal to which activated T  cells are inherently sensitive. 
C 
ancers  escape  immune  clearance  by  a  diversity  of 
mechanisms. Although these include evasive strategies 
to avoid immune recognition, such as disruption of T  cell- 
extracellular matrix interactions  and  aberration  of antigen 
processing and  presentation,  tumors  also  engage  in  active 
modulation and suppression of immune cell function. Local 
immune suppression due to tumor-derived agents is a fea- 
ture of many cancer types. Chemically induced mouse co- 
lon tumors have been shown to cause profound local sup- 
pression ofmucosal inimune function (1). The local immune 
suppression  associated  with  esophageal  squamous  carci- 
noma is mediated by a tumor-derived factor that results in 
suppression and ultimately apoptotic cell death of activated 
lymphocytes (2).  Well-established  tumor-derived immune 
modulatory molecules include downregulatory cytokines, im- 
munosuppressive aminosugars  (free hexosamines)  (3),  and 
gangliosides (4, 5). 
Fas ligand  (FasL) 1 is a key molecule in normal immune 
development,  homeostasis,  modulation,  and  function  (6). 
Ligation onto its receptor, FasR (CD95), on sensitized cells 
~  Abbreviations used in this paper: DOTAP, N-[1-(2,3-Dioleoyloxy)propyl]- 
N,N,N-trimethylamrnoniurn methylsulfate; FasL, Fas ligand; FasR, Fas 
receptor; RT, reverse  transcription. 
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induces  programmed  cell  death,  or  apoptosis.  This  Fas- 
mediated apoptotic death signal has a number of important 
immunological roles. Fas-mediated apoptosis is involved in 
such functions as thymocyte clonal deletion and tolerance 
acquisition (7), T  cell activation-induced cell death (8), im- 
mune response termination (9),  and T  cell-mediated cyto- 
toxicity  (10).  Dysfunction  of Fas-mediated  apoptosis  has 
been associated with lymphoproliferative diseases  and  au- 
toimmunity in humans (11,  12) and mice (13). 
Recently,  two reports established a role for FasL in the 
maintenance of immune privilege in mouse testis  (14)  and 
in the anterior chamber of the eye (15).  FasL expressed in 
these tissues induces apoptosis in activated lymphocytes that 
infiltrate these sites. 
FasL  has  been  found  to  be  constitutively  expressed  in 
some NK lymphomas and T  cell-type large granular lym- 
phocyte leukemias--malignancies of cells that normally ex- 
press FasL upon activation (16).  Because of its central role 
in  lymphocyte modulation  through  delivery of an  apop- 
totic death signal,  we investigated the expression and func- 
tion of FasL in gastrointestinal cancer cells as a candidate for 
tumor-derived immune modulation and hence tumor im- 
nmne escape. 
FasR  expression  and  response  are  variable  in  human 
lymphoid (17,  18) and nonlymphoid malignancies (19), and 
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tumor  immune  escape.  Resistance  to  cellular  apoptotic 
mechanisms in general is thought to contribute to tumori- 
genicity (20),  and  recent  studies have  shown  that  known 
tumor  promoters,  including nicotine,  inhibit both  FasR- 
and TNF-mediated apoptosis (21).  Resistance to FasR has 
been observed in HIV- (22) and HTLV-1  (23) -infected T 
cells and may contribute to viral immune  escape. Because 
of its role in receiving and transducing the FasL-mediated 
apoptotic signal from  cytotoxic T  cells,  and  because  dys- 
function in the FasR-signaling pathway results in resistance 
to Fas-mediated cytotoxicity, we also assessed Fastk expres- 
sion and function on gastrointestinal cancer cells. 
Materials and Methods 
Cells.  OC1  and OC2 are human esophageal squamous carci- 
noma  cell  lines  developed in  our  laboratory  (24).  HT29  and 
SW620 human colon epithelial adenocarcinoma cell lines and the 
Jurkat human T leukemia cell line were obtained from American 
Type Culture Collection (Rockville, MD). All cells were grown 
in  DMEM  supplemented with  10%  FCS  in  a  humidified 10% 
CO2 atmosphere, except as otherwise indicated. 
Reverse  Transcription (RT)  PCR  Detection of FasR  and  FasL 
mRNA Expression.  RNA  was  isolated  from  cells  by  lysis  in 
guanidine thiocyanate (Sigma Chemical Co., St. Louis, MO) fol- 
lowed by phenol extraction and ethanol precipitation, cDNA was 
synthesized  using  AMV  reverse  transcriptase  (Promega  Corp., 
Madison, WI)  and random hexanucleotide primers (Boehringer 
Mannheim GmbH, Mannheim, Germany). 
PCtL was performed on the cDNA using the following sense 
and  antisense  primers,  respectively: FasR.:  CAGAACTTGGA- 
AGGCCTGCATC  and  TCTGTTCTGCTGTGTCTTGGAC; 
FasL: GGATTGGGCCTGGGGATGTTTCA and TTGTGGCT- 
CAGGGGCAGGTTGTTG;  {3-actin: GTGGGGCGCCCCAG- 
GCACCA and CTCCTTAATGTCACGCACGATTTC. 
PCR. primers were designed using the DNASTAR Lasergene 
Primerselect program (DNASTAR, Inc., Madison, WI). Primer 
pairs were  chosen  to  span  introns in  their genomic sequences, 
thus  ensuring  mR.NA-specific amplification.  Primers  were  se- 
lected that showed insignificant homology to any other genes in 
the EMBL DNA sequence database. The FaslL primers span ex- 
ons 3-6 and thus enable amplification of the three splice variants 
of FastL mRNA identified in normal activated lymphocytes that 
code for soluble forms of FasR. (25). 
Thermal cycling was as follows: denaturation at 96~  for 15 s; 
annealing at 55~  for 30 s, and extension at 72~  for 3 min. 40 
cycles were performed for the FasR. and FasL PCRs, 35 cycles for 
the [3-actin  PCiL. Primers were used at a final concentration of 
0.1  ~M each, dNTPs at 50 IxM, and MgC12 at 1.5 raM.  1 U  of 
Taq DNA polymerase was used per 50-txl reaction. PCR prod- 
ucts were  analyzed by electrophoresis through  2%  agarose gels 
and  viewed  under  UV  light  after  ethidium bromide  staining. 
HaelII-digested ~X174  DNA  size  markers  were  used.  PCtL 
product specificities were confirmed by restriction mapping. 
Immunohistochemical Detection of Cell Surface FasL.  SW620  cells 
were  cultured on  glass chamber slides  (Nunc,  Inc.,  Naperville, 
IL).  After fixation in 4%  paraformaldehyde for  1 h,  slides were 
washed twice for 5 rain in a wash buffer containing 50 mM Tris- 
C1, pH 7.6, 50 mM NaC1; and 0.001% saponin. Endogenous per- 
oxidase was quenched with 3% hydrogen peroxide in methanol 
for  5  min.  Slides were  washed  as before except that  the  wash 
buffer for this and all subsequent steps included 1% normal goat 
serum. Slides were then blocked for 1 h in wash buffer containing 
5% normal goat serum. Slides were washed and incubated over- 
night at 4~  with a rabbit polyclonal anti-human  FasL-specific 
IgG (Santa Cruz Biotechnology, Santa Cruz, CA) at 0.1  ~g ml-1 
in wash buffer. Antibody binding was localized using a biotiny- 
lated secondary antibody, avidin-conjugated horseradish peroxi- 
dase, and diaminobenzidine substrate, contained within the Vec- 
tastain ABC detection kit (Vector Laboratories, Inc., Burlingame, 
CA). Staining with isotype-matched rabbit IgG was performed as 
a negative control. The immunizing peptide (NH2-terminal amino 
acids 2-19; Santa Cruz Biotechnology) was included at 1 ~g/ml  -~ 
during the primary antibody incubation as a specific inhibitor of 
FasL staining in additional control staining. Slides were counter- 
stained with hematoxylin. 
Immunofluorescence How  Cytometric Measurement of Cell  Surface 
FasR.  Mouse anti-human FasR. mAb (IgG0 was obtained from 
PharMingen (San Diego, CA). Adherent cells were harvested by 
scraping. Cells were washed in PBS and incubated with 5 Izg/ml  -I 
mAb for 30 n-fin at 4~  and washed in PBS containing 2% FCS. 
FITC-conjugated secondary antibody (Dako Corp., Carpinteria, 
CA) was added to the cells for 30 min at 4~  Cells were washed 
again in PBS containing 2%  FCS. Flow cytometric analysis was 
performed using a flow cytometer (Epics  Elite;  Coulter Corp., 
Hialeah, FL). 10,000  cells were examined for each determination. 
Isotype-matched control antibody was  used in negative control 
staining. 
Assessment of  Anti-FasR mAb CHI 1-inducecl Apoptosis.  Sensitiv- 
ity of cells  to  Fas-mediated apoptosis was determined by treat- 
ment  with  the  agonistic anti-Fastk CH11  IgM  mAb  (Kamiya 
Biomedical Co., Thousand Oaks, CA) or isotype control lgM at 
0.1  b~g/ml -~. After antibody treatment, DNA was isolated from 
cells by the following procedure: cells were lysed in 0.5 ml of a 
buffer consisting of 100  mM Tris-C1, pH 8;  150  mM NaC1;  20 
mM EDTA, and 0.8% sodium lauryl sarcosinate. P,  NA was elim- 
inated by the addition of 10 btl of 1LNase A  (Boehringer Mann- 
heim GmbH; at a concentration of 10 mg/ml in a buffer contain- 
ing 10 mM Tris-C1, pH 7.6, and 15 mM NaC1 that was rendered 
DNase free by boiling for  15  rain followed by slow cooling to 
room temperature) and digesting for 1 h at 37~  Proteins were 
degraded by digestion with  10  ~1  of proteinase K  (Boehringer 
Mannheim GmbH; 20 mg/ml in water) at 50~  for 2 h.  Chro- 
mosomal DNA was then purified by a single phenol extraction 
followed by ethanol precipitation, after which  the DNA pellet 
was redissolved in 20 btl of TE  (10 mM Tris-C1, pH 8.0, and 1 
mM  EDTA).  DNA  integrity  was  assessed  by  electrophoresis 
through  2%  agarose gels,  DNA internucleosomal fragmentation 
or laddering being indicative of apoptosis. 
Antisense Oligonucleotide Treatment.  During antisense  treatment, 
cells  were  maintained  in  reduced-serum  medium  (OptiMEM; 
Sigma Chemical Co.) to limit the degradation of oligonucleotides 
by  serum-derived  nucleases  (26).  Oligonucleotide uptake  was 
facilitated by  complexing  with  the  cationic  lipid  transfection 
reagent  N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammo- 
nium  methylsulfate  (DOTAP),  which  has  been  shown  to  en- 
hance DNA uptake by cells (27).  Complexing with DOTAP has 
also  been  shown  to  protect  oligonucleotides from  nucleolytic 
degradation within the cell. Cells were treated with oligonucle- 
otides and the cationic lipid vector DOTAP (Boehringer Mann- 
heim GmbH)  at final concentrations of 10 and  13  ~M, respec- 
tively for  24  h.  Oligonucleotides and  the  transfection  reagent 
DOTAP  were  complexed at  100￿  concentration for  5  rain  at 
1076  The Fas Counterattack Figure 1.  FasR  and FasL mRNA expression in gastrointestinal  cancer 
cells. Expression  was analyzed  by RT-PCR of equalized input RNA iso- 
lated from each cell line. Resting (R) and PHA-activated (A) PBL were 
used as negative and positive controls, respectively. ]3-actin control PCR 
was performed to monitor RT-PCR amplification  efficiency, mRNA- 
specific amplification  product bands  for FasR (682 bp), FasL (344 bp), and 
13 actin (540 bp) are indicated. The nfinor band (619 bp) obtained from 
the HL60 neutrophil control mRNA corresponds to the FasR Delta 1 
mRNA splice variant, which encodes a soluble form of FasR. qbX174- 
HaeIIl size markers (M) were used. 
37~  before addition to cells. After treatment, cells were washed 
free of the oligonucleotide/DOTAP-containing  medium and re- 
suspended in fresh medium before further manipulation. The an- 
tisense PCR primers for FasR and FasL also served  as antisense 
oligonucleotides. The control nonsense oligonucleotide had the 
following nonspecific  nucleotide  sequence:  AATTCTACTG- 
GTTGTTCTGCTGGT. 
Coculture DNA Fragmentation  Assay (The  JAM Test).  Target  Jur- 
kat cell death resulting from coculture with effector colon cancer 
cells was  quantitated by measurement of target  cell DNA frag- 
mentation using the JAM  test  (28). The adherent colon cancer 
cells were seeded into the wells of a flat-bottomed 96-well micro- 
titer plate  at cell numbers appropriate  to give the required E/T 
ratios. The cells thus seeded were incubated at 37~  for 24 h and 
aspirated before the addition of 2 ￿  104jurkat target cells. Target 
cell DNA was labeled by prior incubation with  10  p,  Ci/ml of 
[3H]TdR  at  37~  for  3  h.  Oligonucleotide-treated cells were 
washed  in culture medium (OptiMEM) before labeling. Labeled 
target cells were washed and added to the seeded effector cells in 
a final volume of 200 Ixl per well. After coculture at 37~  for 8 h, 
the cells were removed from the wells by pipetting up and down 
five times  and were collected by filtration onto glass fiber filters 
using a 96-well filtration unit. The cells were hypotonically lysed, 
and  fragmented DNA  was  washed  through  the  filter  by  four 
washes of 0.25  ml of water.  The radioactivity of intact chromo- 
somal DNA retained on each filter was measured by liquid scin- 
tillation counting. Specific  cell  killing was  calculated  using the 
following equation: 
% Specific killing =  (S -  E/S)  ￿  100 
where E (experimental)  is cpm of retained DNA in the presence 
of effector cells, and S (spontaneous)  is cpm of retained DNA in 
the absence of effector cells. Use of the value of S rather than to- 
tal incorporated counts in the equation corrects  for spontaneous 
target cell DNA fragmentation during the assay. 
Results  and Discussion 
FasR-bearing Colon  Cancer  Cells Are Resistant to Fas-medi- 
ated Induction of Apoptosis.  RT-PCR  results show that both 
colon  adenocarcinoma cell  lines HT29  and  SW620,  but 
neither esophageal squamous carcinoma ceU lines OC1  or 
OC2,  express FasR mRNA  (Fig 1).  The FasR RT-PCR 
assay was controlled by equalization of input RNA for each 
cell line. Comparable amplification efficiencies were achieved 
in all RNA samples as evidenced by the uniformity of con- 
trol  [3-actin  RT-PCR  product  yields.  Equivalent  FasP( 
PCR product band intensities suggest that both HT29 and 
SW620 express levels of FasR qualitatively similar to  that 
expressed in PHA-activated PBL.  This was  confirmed by 
detection of cell surface FasR on HT29 and SW620 cells 
by immunofluorescence flow cytometry after staining with 
a  FasR-specific  mAb  (Fig.  2).  FasR  staining was  absent 
from OC1 and OC2. 
FasR expression alone does not imply sensitivity to Fas- 
mediated apoptosis,  and  other  factors  determine whether 
the FasL signal is transduced. Low FasR-expressing malig- 
nant glioma cells showed that a  critical level of FasR ex- 
pression is required for apoptotic signaling. Simply elevat- 
ing  subcritical  FasR  expression  rendered  these  cells  Fas 
sensitive (29). Mutations of p53 have been associated with 
lack  of FasR  expression in transformed cells  (30).  IFN-~/ 
and TNF-~x are required to potentiate FasR in some nor- 
mal (31-33) and malignant (29, 34)  cells.  The Fas-sensitiz- 
ing effect of these cytokines is partly associated with induc- 
tion  or  upregulation of FasR  expression.  Indeed,  IFN-3' 
has been shown to elevate FasR expression in HT29 (35). 
As  our  results  indicate,  HT29  and  SW620  constitutively 
express  levels of FasR  mRNA  comparable with  that  ex- 
pressed  in  activated  lymphocytes  and  cell  surface  FasR 
comparable with that expressed in Fas-sensitive  Jurkat cells 
Log Fluorescence Intensity 
Figure  2.  Cell surface FasR 
expression in gastrointestinal  can- 
cer cells. 106 cells were stained 
with  mouse anti-human  FasR 
monoclonal  IgG  followed by 
staining  with a secondary FITC- 
conjugated anti-mouse IgG anti- 
body. FasR expression was  de- 
termined  by  flow cytometric 
analysis. The profiles obtained by 
FasR antibody staining (shaded 
peaks)  relative to  control  anti- 
body staining (open peaks) are 
shown. 
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apoptosis.  DNA was isolated  from cells after  treatment  with  anti-Fasl< 
CHll  mAb (0.1 ~tg/m1-1) for 6 and 24 h or with isotype  control mouse 
lgM  for  24  h  (Ctrl).  DNA  integrity  was  assessed  after  electrophoresis 
through a 2% agarose gel. Sizes of markers (M) are indicated  in bp. DNA 
fragmentation or laddering is indicative  of apoptosis. 
(see  Fig.  5).  Hence,  receptor level should be adequate  for 
Fas signaling in these cells. 
FasP,  function  in  HT29  and  SW620  was  assessed  by 
treatment of these cells  with the  anti-FasR agonistic mAb 
CH11  and analysis  of anti-FaslL-induced internucleosomal 
DNA  cleavage.  After  6-  and  24-h  incubations  with  this 
mAb, neither HT29  nor SW620  showed any evidence of 
apoptosis using the DNA fragmentation assay (Fig. 3). After 
CH11  treatment,  both  cell  types showed  intact  chromo- 
somal DNA, equivalent in integrity to untreated cells incu- 
bated for 24 h. Both cell lines were as refractory to the ef- 
fect of the  anti-FasR agonistic mAb as the  FasR-negative 
OC2 cell line. Under identical conditions, treatment of the 
Fas-sensitive Jurkat  control  cells  with  CH11  resulted  in 
pronounced apoptotic DNA fragmentation into DNA lad- 
ders  of nucleosomal  oligomers  of ~'-,180 bp  after  6  h  of 
treatment  relative  to  the  intact  DNA  of untreated Jurkat 
cells  incubated  for  24  h.  Hence,  HT29  and  SW620,  al- 
though expressing cell surface FasR, are resistant to induc- 
tion of apoptosis through agonistic engagement of FaslL. 
Expression  of soluble,  potentially  antagonistic  forms of 
FasP-,  from  splice  variants  of  FasR  mRNA  lacking  the 
transmembrane  exon  has  been  shown  in  some  cells  (36) 
and may contribute to Fas resistance in certain pathological 
conditions, including SLE (37,  38). Three splice variants of 
FasP, mlLNA have been detected in normal activated lym- 
phocytes (25).  Although a minor band was observed in the 
P,T-PCIL products from the HL60 control mlLNA, which 
corresponds to the Faslk Delta 1 mRNA splice variant, no 
PCP, product bands  derived from amplification of spliced 
variants Delta  1,  2,  or 3  (619-,  435-,  or 372-bp  expected 
product  sizes,  respectively)  were  detectable  in  any  of the 
other cell lines.  Hence, expression of soluble FasP, can be 
eliminated as a  mechanism of Fas  resistance in  HT29  and 
SW620. 
The level of expression of genes involved in the control 
of apoptosis can affect the Fas sensitivity of cells. Expression 
and upregulation of bcl 2 has been implicated in a variety of 
cell types as protective against apoptotic cell death,  includ- 
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ing Fas-mediated apoptosis (34, 39-41). Using immunofluo- 
rescence flow cytometry, we found that although  SW620 
expresses bcl 2,  the level of expression in HT29 was negli- 
gible  (unpublished  observations),  so  that  Fas  resistance  in 
these  colon  adenocarcinoma  cells  does  not  corelate  with 
bcl 2 expression. 
Colon Cancer Cell SW620 Expresses FasL.  RT-PCR  re- 
sults  show  that  SW620,  but  none  of the  other  cell  lines 
HT29, OC1, or OC2, expresses FasL mRNA (Fig.  1). The 
FasL PCR was performed on the same cDNA preparations 
used for the FasP,. and [3-actin control ILT-PCP, assays and 
was therefore similarly controled for equalization  of input 
RNA  and  amplification  efficiency.  By  comparing  FasL 
R.T-PCR band intensities, SW620 expresses a level of FasL 
mP,  NA  qualitatively much  higher  than  that  expressed by 
PHA-activated PBL. Immunohistochemical staining shows 
that SW620 expresses cell surface FasL (Fig.  4).  FasL speci- 
ficity was confirmed as staining of SW620 was inhibited by 
inclusion of the immunizing FasL peptide as a competitive 
inhibitor in  the  primary antibody incubation.  These find- 
ings show that FasL expression is not restricted to lymphoid 
cells and tissues  and sites of immune privilege in the body. 
Using  Fas-sensitive Jurkat  indicator  cells,  FasL  activity 
was  undetectable  in  culture  fluid  conditioned  by  SW620 
cells. Jurkat cells  were incubated for 24 h  in  SW620  cell- 
conditioned  medium or  mixtures  of cell-conditioned  and 
fresh  media.  This  treatment  failed  to  cause  induction  of 
apoptosis above background levels (10-15% in Jurkat cells) 
detectable by either the DNA fragmentation assay or flow 
cytometric  detection  of apoptotic  bodies  after propidium 
iodide  staining  of treated cells  (unpublished  observations). 
This suggests that the FasL expressed by SW620 is not shed 
by these cells. 
Fas-sensitiue durkat  T  Cells Are  Killed  by  Coculture with 
SW620.  Having demonstrated  that  SW620  cells  express 
FasL,  but are themselves resistant to  Fas-mediated apopto- 
sis, we wished  to  ascertain if the  FasL  was functional  and 
therefore if SW620 could induce apoptosis in Fas-sensitive 
cells.  In  particular,  we  wished  to  know if SW620  cancer 
cells  could kill activated,  Fas-sensitive T  cells  in  this way, 
which would suggest a potential mechanism of tumor im- 
mune escape. To address this question,  we used Jurkat as a 
target cell in coculture experiments with SW620. Jurkat is 
a Fas-sensitive cell line ofT cell origin that is constitutively 
activated  and  has  been  widely  used  experimentally  as  a 
model for activated T  cells, with which it shares functional 
similarities. Jurkat  cells  are  particularly  appropriate  target 
cells  for  investigating  putative  FasL  activity  because  they 
are insensitive to TNF-o~, another major mediator ofapop- 
totic cell death, and to lymphotoxin a  (8). 
Using  the  DNA  gel  fragmentation  assay,  we  observed 
that DNA from cocultured Jurkat and SW620 cells showed 
pronounced nucleosomal DNA laddering relative to either 
cell line incubated alone or to Jurkat cells  cocultured with 
FasL-negative HT29 colon cancer cells.  These preliminary 
results  were  suggestive  of apoptotic  killing  of the Jurkat 
cells  by the  Fas-resistant,  FasL-expressing SW620  cells.  A 
more  sensitive  and  controled  coculture  cell  killing  assay, Figure  4.  Colon  cancer  cell 
SW620  expresses cell  surface 
FasL. SW620 cells were stained 
with  a  rabbit  polyclonal  anti- 
human  FasL-specific IgG  and 
counterstained with hematoxylin 
(purple). Positive staining (brown) 
was  obtained  (A), whereas iso- 
type control rabbit IgG failed to 
stain the cells (B). Positive stain- 
ing was reduced by coincubation 
of the primary antibody with the 
FasL immunizing  peptide  (not 
shown). 
the JAM test (28), was adopted to resolve the source of the 
apoptotic DNA  fragments observed after coculture of  Jur- 
kat with SW620  cells. By prelabeling the target Jurkat cell 
DNA  with  [3H]TdR,  specific DNA  fragmentation  of the 
target  cells in  response  to  the  cocultured  effector  SW620 
cells was  quantified.  As seen  in  Fig.  6  A,  SW620  effected 
30% specific killing of  Jurkat cells at an E/T ratio of 25:1  in 
an 8-h incubation. Cell killing increased with increasing E/T 
ratio,  and  pronounced  killing (>20%)  occurred  even  at  a 
low E/T  ratio equivalent to 5"1. 
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FasR-specific Antisense Oligonudeotide Treatment Protects  Jur- 
kat Cells  from Killing by SW620.  To  determine  whether 
the killing of  Jurkat cells by coculture with SW620 was Fas 
mediated,  we  used  Fas-specific  antisense  oligonucleotide 
treatment to  render Jurkat cells temporarily FasR negative 
for  use  as  control  targets.  The  efficacy of FasR  antisense 
oligonucleotide treatment was verified by immunofiuores- 
cence  flow  cytometry of treated Jurkat  cells after staining 
with a Fas-specific mAb. In the FasR antisense oligonucle- 
otide-treated Jurkat cells there was a reduction of cell sur- Figure 5.  Inhibition of FasP, expression in Jurkat T cells by FasP,-spe- 
cific antisense oligonucleotide treatment.  DOTAP-mediated Fas-specific 
or nonspecific control  oligonucleotide treatment  of  Jurkat  cells was per- 
formed for 24 h in optimized reduced-serum medium (OptiMEM). After 
oligonucleotide treatment,  10  ~' cells were stained with mouse anti-human 
FasR. monoclonal IgG followed by staining with a secondary FITC-con- 
jugated  anti-mouse IgG antibody.  FasR. expression was determined  by 
flow cytometric analysis.  The profiles obtained by Fasl< antibody staining 
(shaded peaks) relative to control antibody staining (open peaks) are shown 
for untreated  (A), nonsense oligonucleotide-treated  (B), and FasR-spe- 
cific antisense oligonucleotide-treated Jurkat T ceils (C). 
face  FasR  staining  to  background  levels.  In  the  control 
nonsense  oligonucleotide-treated  cells,  staining  for  FasR, 
was  equivalent  to  that  of untreated Jurkat  cells  (Fig.  5). 
This indicates that  antisense  oligonucleotide treatment  ef- 
fectively and specifically abolishes FasR expression inJurkat 
cells. 
In the JAM cell-kilhng test, it was found that FasR anti- 
sense  oligonucleotide treatment completely protected Jur- 
kat cells from killing by SW620 at all the tested E/T  ratios 
(Fig.  6  A).  Control  nonspecific oligonucleotide treatment 
had no effect on killing of  Jurkat cells by SW620. As FasR 
antisense-treated  Jurkat  ceils  were  demonstrated  to  be 
FasP,.  negative as  opposed  to  the  FasP,-positive nonsense- 
oligonucleotide treated  cells  (Fig.  5),  these  results strongly 
suggest  that  SW620  kills Jurkat  ceils  in  a  Fas-dependent 
manner. 
FasL-specific Antisense  Treatment  Inhibits  SW620  Killing  of 
Jurkat  T  Cells.  To confirm that SW620-induced killing of 
Jurkat T  cells was mediated by FasL, the SW620 cells were 
tested  for  cytotoxic  activity  after  pretreatment  with  anti- 
sense oligonucleotides specific for the FasL gene. The JAM 
test  was  performed  as  described  at  an  E/T  ratio  of 10:1, 
previously shown to  result in significant cell killing (Fig. 
6 A), with FasL-specific antisense and control nonsense oli- 
gonucleotide-treated  SW620  effector  cells.  Although  our 
results indicated that  SW620  did not shed  FasL  at  detect- 
able  levels,  the  SW620  cells  were  washed  rigorously  to 
eliminate the possibility of residual soluble FasL remaining 
in the culture medium of the oligonucleotide-treated cells. 
The  results show  that  FasL  antisense treatment  resulted in 
significant  inhibition,  by  ~60%,  of the  killing  effect  of 
40- 
A 








Figure  6.  FasL-expressing colon cancer cell SW620 kills  Jurkat T cells 
in  a  Fas-dependent  manner.  [3H]TdR.-labeled Jurkat  target  cells were 
cocultured with SW620 effector cells at the indicated E/T ratios. Target 
cell death was determined  8 h later by measuring DNA fragmentation of 
the 3H-labeled target cell DNA (JAM test). Specific cell death was calcu- 
lated relative to  spontaneous  cell death  occurring  in target cells alone. 
Each percent of specific killing value represents the mean of quadruplicate 
coculture  cell-killing assays. (A)  FasP--specific antisense oligonucleotide 
treatment ofJurkat T cells results in complete protection  from killing by 
SW620 colon cancer cells. Nonspecific "nonsense"  control oligonucleo- 
tide-treated Jurkat cells (FasR positive) are killed by coculture with SW620 
cells (open squares). FasR-specific antisense oligonucleotide-treated  Jurkat 
cells (FasR negative) are completely immune to killing by SW620 (solid 
circles). (B) FasL-specific antisense ohgonucleotide  treatment inhibits kill- 
ing ofJurkat T  cells by SW620.  FasL-specific antisense oligonucleotide 
treatment results in 60% inhibition of killing ofJurkat T cells by SW620 
(hatched bar) relative to  nonspecific  "nonsense"  oligonucleotide-treated 
SW620 cells (solid bar). An E/T ratio of 10:1 Was used. 
SW620  on Jurkat T  cells relative to the nonsense oligonu- 
cleotide-treated control SW620 cells (Fig. 6  B). These data 
suggest that killing of  Jurkat cells was mediated by FasL ex- 
pressed by SW620 cells. 
The Fas Counterattack.  We demonstrate that colon can- 
cer cell SW620 expresses functional FasL and kills the acti- 
vated T  cell, Jurkat,  in a  Fas-dependent manner. We  also 
show  that  colon  cancer  cells  SW620  and  HT29  express 
Figure  7.  Proposed Fas counterattack model of tumor immune escape 
in colon cancer. The colon cancer celt expresses FasP,. but is resistant to 
Fas-mediated T  cell cytotoxicity.  However,  the  colon cancer  cell ex- 
presses functional FasL, which rapidly induces apoptosis in Fas-sensitive 
activated T cells, which infiltrate the tumor. 
1080  The Fas Counterattack FasR but are resistant to Fas-mediated apoptosis. Although 
the  cause(s)  of Fas  resistance  in  these  cells  remains  to be 
elucidated,  our  results  eliminate  underexpression  of cell 
surface  FasK  or expression  of soluble  Fastk  as  reasons  for 
resistance. 
Our results suggest a Fas counterattack model as a mech- 
anism of immune escape in colon tumors (Fig. 7). It shows 
how a tumor may exploit an intrinsic cell death program of 
the activated T  cells that infiltrate  it. Essentially the cancer 
cell counterattacks the activated cytotoxic T  cell that chal- 
lenges it with  one  of the  T  cell's own principal  cytotoxic 
armaments:  FasL.  The  counterattack  is rendered  more  ef- 
fective as  the  cancer cell itself is  resistant  to the  cytotoxic 
effect  of FasL,  whereas  the  attacking  T  cell  is  inherently 
sensitive to its apoptotic death signal. 
This mechanism is analogous to the  recently established 
role of FasL in mediating immune privilege in mice.  FasL 
expressed in tissues and at sites of immune privilege, such as 
the testis (14) and the anterior chamber of the eye (15), in- 
duces  apoptosis  in  activated  lymphocytes  that  infiltrate 
these sites.  Expression of functional FasL by human tumors 
could conceivably confer immune-privileged status on such 
malignancies. 
Other  selective  advantages  could  theoretically  accrue 
from expression by a tumor of such an important biological 
death factor to which the tumor cells themselves are resis- 
tant.  FasL expression could conceivably facilitate the estab- 
lishment  of tumors or tumor metastases  at sites  where  the 
indigenous  cells  express  FasR  and  can  therefore  be  ren- 
dered subject to the  FasL-mediated cytotoxicity of the tu- 
mor. In this respect it is of interest that the FasL-expressing 
SW620 cell line was derived from a lymph node metastasis 
of a primary colon carcinoma. 
Subsequent  to  the  investigation  of FasL expression  and 
function in SW620, using KT-PCK,  two other colon ade- 
nocarcinoma cell lines, T84 and CaCo2, were found to ex- 
press FasL mRNA. This suggests that FasL expression may 
be a prevalent feature of colon carcinoma. 
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